Tenax Therapeutics Inc. (TENX)
NASDAQ: TENX
· Real-Time Price · USD
5.85
-0.10 (-1.68%)
At close: Aug 15, 2025, 12:32 PM
-1.68% (1D)
| Bid | 4.29 |
| Market Cap | 24.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.21M |
| EPS (ttm) | 1.69 |
| PE Ratio (ttm) | 3.46 |
| Forward PE | -2.08 |
| Analyst | Buy |
| Ask | 7.55 |
| Volume | 7,462 |
| Avg. Volume (20D) | 26,020 |
| Open | 5.86 |
| Previous Close | 5.95 |
| Day's Range | 5.85 - 6.01 |
| 52-Week Range | 3.25 - 7.89 |
| Beta | 1.46 |
About TENX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TENX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TENX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
+3.15%
Tenax Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
+10.65%
Tenax Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a price target of $16.
4 months ago · seekingalpha.com
Tenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-m...